JP2016530889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530889A5 JP2016530889A5 JP2016542337A JP2016542337A JP2016530889A5 JP 2016530889 A5 JP2016530889 A5 JP 2016530889A5 JP 2016542337 A JP2016542337 A JP 2016542337A JP 2016542337 A JP2016542337 A JP 2016542337A JP 2016530889 A5 JP2016530889 A5 JP 2016530889A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hbv
- cells
- cdrs
- huh7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13184635.4 | 2013-09-16 | ||
| EP13184635 | 2013-09-16 | ||
| PCT/EP2014/069675 WO2015036606A1 (en) | 2013-09-16 | 2014-09-16 | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530889A JP2016530889A (ja) | 2016-10-06 |
| JP2016530889A5 true JP2016530889A5 (enExample) | 2019-04-11 |
| JP6599338B2 JP6599338B2 (ja) | 2019-10-30 |
Family
ID=49165642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542337A Active JP6599338B2 (ja) | 2013-09-16 | 2014-09-16 | Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10059767B2 (enExample) |
| EP (1) | EP3046938B1 (enExample) |
| JP (1) | JP6599338B2 (enExample) |
| CN (2) | CN111606998B (enExample) |
| CA (1) | CA2924252C (enExample) |
| ES (1) | ES2773306T3 (enExample) |
| RU (1) | RU2671089C2 (enExample) |
| WO (1) | WO2015036606A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2550384T3 (es) | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
| ES2773306T3 (es) | 2013-09-16 | 2020-07-10 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Polipéptidos bi o multiespecíficos de unión a antígenos de superficie de células efectoras inmunitarias y antígenos de VHB para tratar infecciones por VHB y estados asociados |
| RU2733496C2 (ru) * | 2015-03-16 | 2020-10-02 | Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) | Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний |
| CN106349391A (zh) * | 2015-07-17 | 2017-01-25 | 中国科学院深圳先进技术研究院 | Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用 |
| CN114853907B (zh) | 2015-11-13 | 2025-06-27 | 达纳-法伯癌症研究所有限公司 | 用于癌症免疫疗法的nkg2d-ig融合蛋白 |
| CN105505872B (zh) * | 2016-02-16 | 2019-01-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种致敏nk细胞的方法及组合物 |
| CN107129537A (zh) * | 2016-02-29 | 2017-09-05 | 北京赛诺泰生物科技有限公司 | 抗乙型肝炎病毒的免疫反应性细胞 |
| AU2017337073A1 (en) * | 2016-09-30 | 2019-04-18 | Baylor College Of Medicine | Antibody based gene therapy with tissue-directed expression |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN109265559B (zh) * | 2018-09-25 | 2021-12-07 | 山东兴瑞生物科技有限公司 | 嵌合抗原受体、其制备方法、利用其修饰的nk细胞及治疗hbv感染的应用 |
| WO2020132024A1 (en) * | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2022081529A1 (en) * | 2020-10-12 | 2022-04-21 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| CN112592902B (zh) * | 2020-12-16 | 2022-03-29 | 熊猫乳品集团股份有限公司 | 一种生物活性肽aseppvldvkrpflc及其制备方法和应用 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN114573705B (zh) * | 2022-03-17 | 2024-05-14 | 杭州师范大学 | 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用 |
| KR20250042205A (ko) * | 2022-06-27 | 2025-03-26 | 에스씨지 셀 테라피 피티이. 리미티드 | HBV 표면 항원 (HBsAg) 및 CD3에 대한 이중 특이적 항체 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| IL154751A0 (en) * | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| JP4906094B2 (ja) * | 2004-01-16 | 2012-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レセプターを活性化し得る融合ポリペプチド |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2008119565A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| US8999398B2 (en) * | 2009-11-06 | 2015-04-07 | Transtarget Inc. | Polyclonal bispecific antibody compositions and method of use |
| WO2012156430A1 (en) * | 2011-05-17 | 2012-11-22 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| EP2524699A1 (en) * | 2011-05-17 | 2012-11-21 | Trion Research GmbH | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
| WO2013102123A2 (en) * | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| ES2773306T3 (es) | 2013-09-16 | 2020-07-10 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Polipéptidos bi o multiespecíficos de unión a antígenos de superficie de células efectoras inmunitarias y antígenos de VHB para tratar infecciones por VHB y estados asociados |
-
2014
- 2014-09-16 ES ES14771250T patent/ES2773306T3/es active Active
- 2014-09-16 US US15/021,916 patent/US10059767B2/en active Active
- 2014-09-16 EP EP14771250.9A patent/EP3046938B1/en active Active
- 2014-09-16 CA CA2924252A patent/CA2924252C/en active Active
- 2014-09-16 JP JP2016542337A patent/JP6599338B2/ja active Active
- 2014-09-16 CN CN202010449532.9A patent/CN111606998B/zh active Active
- 2014-09-16 RU RU2016114504A patent/RU2671089C2/ru active
- 2014-09-16 CN CN201480050976.8A patent/CN105636982B/zh active Active
- 2014-09-16 WO PCT/EP2014/069675 patent/WO2015036606A1/en not_active Ceased
-
2018
- 2018-08-24 US US16/112,431 patent/US10730943B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| CN112437776B (zh) | 间皮素和cd137结合分子 | |
| US9828432B2 (en) | Cancer treatment and monitoring methods using OX40 agonists | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| JP2018501197A5 (enExample) | ||
| KR20210031479A (ko) | Cd137 및 ox40에 결합하는 항체 분자 | |
| JP2020526211A5 (enExample) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2018508483A5 (enExample) | ||
| JP2018512170A5 (enExample) | ||
| CN116003608A (zh) | 拮抗性cd40单克隆抗体及其用途 | |
| JP2016527286A5 (enExample) | ||
| JP2016509582A5 (enExample) | ||
| JP7650351B2 (ja) | 非古典的ｈｌａ－ｉとネオアンチゲンとを含む複合体を標的とする抗体、およびその使用方法 | |
| WO2020043683A1 (en) | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| JP2020532304A5 (enExample) | ||
| Long et al. | HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice | |
| Mendoza-Valderrey et al. | Next generation immuno-oncology strategies: unleashing NK cells activity | |
| US20240011046A1 (en) | Oncolytic viruses encoding recombinant transforming growth factor (tgf)-beta monomers and uses thereof | |
| CN116457018A (zh) | Herv-k抗体治疗剂 | |
| US20240409653A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| TW201713346A (zh) | 調控免疫反應之方法及抗體 | |
| Rao et al. | CD4+ T cells facilitate the RT-induced abscopal effect by promoting antigen cross-presentation to CD8+ T cells at unirradiated tumor sites |